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The therapeutic efficacy of an antimicrobial peptide, human lactoferrin 1-11 (hLF1-11), was investigated in
a model of chronic methicillin-resistant Staphylococcus aureus (MRSA) (gentamicin susceptible) osteomyelitis
in rabbits. We incorporated 50 mg hLF1-11/g or 50 mg gentamicin/g cement powder into a calcium phosphate
bone cement (Ca-P) and injected it into the debrided tibial cavity, creating a local drug delivery system. The
efficacy of hLF1-11 and gentamicin was compared to that of a sham-treated control (plain bone cement) (n 
6) and no treatment (infected only) (n  5). The results were evaluated by microbiology, radiology, and
histology. MRSA was recovered from all tibias in both control groups (n  11). On the other hand, hLF1-11
and gentamicin significantly reduced the bacterial load. Furthermore, no growth of bacteria was detected in
five out of eight and six out of eight specimens of the hLF1-11- and gentamicin-treated groups, respectively.
These results were confirmed by a significant reduction of the histological disease severity score by hLF1-11
and gentamicin compared to both control groups. The hLF1-11-treated group also had a significantly lower
radiological score compared to the gentamicin-treated group. This study demonstrates the efficacy of hLF1-11
incorporated into Ca-P bone cement as a possible therapeutic strategy for the treatment of osteomyelitis,
showing efficacy comparable to that of gentamicin. Therefore, the results of this study warrant further
preclinical investigations into the possibilities of using hLF1-11 for the treatment of osteomyelitis.
Osteomyelitis causes major morbidity and remains the most
feared and difficult infection to treat in orthopedic surgery.
Radical surgical debridement with local administration of an-
tibiotics e.g., gentamicin-loaded polymethyl methylacrylate
(PMMA) beads in combination with systemic antibiotics, has
been the treatment of choice (7, 27, 28). The major disadvan-
tage of PMMA beads is the need to remove them after they
have eluded their antibiotics, requiring an additional surgical
procedure (7, 27, 28). Numerous investigations have been per-
formed to develop other resorbable/biodegradable carriers for
several antibiotics (1, 9).
Gentamicin has long been the primary choice of orthopedic
surgeons for local treatment of osteomyelitis (13, 28). This
aminoglycoside is a broad-spectrum antimicrobial agent, which
is active against both gram-positive and gram-negative bacteria
(5). The long-term release profiles of gentamicin from PMMA
and calcium phosphate bone cements have been demonstrated
in kinetic release studies (9, 26). Overall, the use of gentami-
cin-loaded PMMA beads results in high local antibiotic bone
and soft tissue concentrations versus low systemic concentra-
tions, reducing systemic side effects (26). On the contrary, the
high systemic dosage of gentamicin needed to reach sufficient
tissue penetration would create serious toxic side effects (2).
Over the past few years, studies have shown an increase in
antibiotic-resistant bacteria such as gentamicin-resistant Staph-
ylococcus aureus and methicillin-resistant Staphylococcus au-
reus (MRSA) (30). The prevalence of MRSA in nosocomial
infections has exceeded 30% in some countries, e.g., southern
Europe and the United States (8, 30). Several authors have
also demonstrated the presence of gentamicin-resistant staph-
ylococci after gentamicin-loaded PMMA bead therapy, raising
concern about the efficacy of this treatment option (14, 25).
Furthermore, reports on staphylococcal infections with re-
duced susceptibility or resistance to vancomycin are emerging
(29). As current antibiotic therapy options are becoming lim-
ited for staphylococcal infections, there is an urgent need for
new antimicrobial agents to combat these resistant pathogens.
Antimicrobial peptides are a new and promising class of
antimicrobial agents derived from naturally occurring peptides
(4). These peptides are found on epithelial surfaces, in secre-
tion fluids, and in neutrophils and thus form a first line of host
defense as part of the innate immune system (31). Further-
more, they are thought to have a diminished tendency to in-
duce resistance because of the evolutionary difficulty in chang-
ing bacterial membrane structure (4, 31). These properties
together with the antimicrobial activity against a broad variety
of pathogens have made antimicrobial peptides attractive can-
didates for antimicrobial drug development (24).
The antimicrobial peptide human lactoferrin 1-11 (hLF1-11)
is derived from the active domain of human lactoferrin (N-
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terminal amino acids 1 to 11) (12). hLF1-11 has a broad anti-
microbial spectrum in vitro against both bacteria and fungi (11,
12, 16). Furthermore, Nibbering et al. demonstrated the effi-
cacy of hLF1-11 in vivo, reducing the number of bacteria
(MRSA) after systemic administration in the mouse thigh in-
fection model (16).
In the light of antimicrobial resistance and the urgent need
for new antimicrobial agents, we previously investigated the
efficacy of using calcium phosphate bone cement as a carrier
for hLF1-11 (22). In general calcium phosphate bone cements
showed a high and prolonged in vitro release of hLF1-11 in its
biologically active form (22). Furthermore, we also showed
that hLF1-11 incorporated into calcium phosphate bone ce-
ment can prevent S. aureus osteomyelitis in rabbits (21). There-
fore, the aim of the present investigation was to evaluate and
compare the performance of hLF1-11 and gentamicin incor-
porated into calcium phosphate bone cement to treat MRSA
osteomyelitis in rabbits.
MATERIALS AND METHODS
Experimental design. The study was set up according to the well-described
osteomyelitis model of Norden et al. (18). The proximal right tibias of 27 New
Zealand White rabbits were inoculated with approximately 3 106 CFU MRSA.
After 3 weeks, on day 21 treatment was initiated, except for five control animals
which were sacrificed at this time point. Six animals were assigned to the sham-
treated control group (n  6), receiving a thorough debridement and plain
calcium phosphate bone cement (Calcibon, Biomet Merck, Darmstadt, Ger-
many). The remaining 16 animals were also thoroughly debrided and received
either 50 mg hLF1-11 (n  8) or 50 mg gentamicin sulfate (n  8) per gram of
bone cement powder (approximately 20 mg/kg body weight). On day 42, 3 weeks
after treatment, all treated animals were sacrificed and treatment outcome was
assessed by radiology, microbiology, and histology.
Animals. Female New Zealand White rabbits (3.5 to 4 kg) were obtained 3
weeks prior to surgery and allowed to acclimatize to the Clinical Animal Labo-
ratory, Vrije Universiteit Medical Center. The animals were housed in groups of
10 and were allowed water and antibiotic-free rabbit diet ad libitum. The exper-
imental protocol was approved by the Animal Ethics Committee of the Vrije
Universiteit Medical Center.
Bacterial strain. The strain which was used for this study was a methicillin-
resistant Staphylococcus aureus (MRSA) strain W234 isolated from a patient with
chronic osteomyelitis. Besides resistance to all -lactam antibiotics, the strain
was also resistant to erythromycin, tetracycline, trimethroprim-sulfamethoxazole,
and quinolones, but was susceptible to clindamycin, rifampin, aminoglycosides,
and glycopeptides (not shown).
An overnight culture was grown in brain heart infusion (BHI) broth and
washed in phosphate-buffered saline (PBS). Subsequently, aliquots were pre-
pared and stored at 80°C. The numbers of viable CFU were determined in the
defrosted aliquots by serial dilution and plating on blood agar. At the day of
surgery a fresh aliquot was defrosted, and a bacterial suspension of approxi-
mately 3  107 CFU/ml was prepared in PBS. The tibial canal was inoculated by
injection of 0.1 ml bacterial suspension (3  106 CFU). After surgery, the
inoculates were serially diluted, plated on blood agar, and cultured to confirm the
number of viable bacteria.
Surgery. The anesthesia was exactly the same for both the inoculation and the
treatment of infection. After weighing, the animals were given a subcutaneous
injection of xylazine, 2.5 mg/kg (Xylalin, CEVA Sante Animale, Maassluis, The
Netherlands), and ketamine, 62.5 mg/kg (Aescoket, Aesculaap, Boxtel, The
Netherlands), between the shoulder blades. Once sedated, the right knee area
was shaven and washed with iodine solution. Subsequently, lidocaine 5 mg/kg
(Pharmacy Vrije Universiteit Medical Center, Amsterdam, The Netherlands)
was injected around the tuberculum and tibial plateau of the right tibia. Preop-
erative blood samples were drawn from the auricular vein for the determination
of white blood cell count (WBC) and erythrocyte sedimentation rate (ESR). The
animals were then placed on their back, the skin painted again with iodine and
the surgical area isolated with sterile drapes. During surgery, the anesthesia was
maintained by free-flow inhalation of a gas mixture containing 45% oxygen;
53.5% air and 1.5% isoflurane (Forene, Abbot BV, Hoofddorp, The Nether-
lands). Postoperative pain relief was provided by subcutaneous injection of 0.15
mg buprenorphine, which was repeated if necessary.
Inoculation of the tibia. A small stab incision was made over the tuberculum
of the right tibia, and subsequently a 1.8-mm drill hole was made with a K-wire
mounted on a hand-held drill. Then a 16-gauge needle was inserted into the tibial
cavity. Subsequently, 100 l of 5% sodium morrhuate (Scleromate, Glenwood,
Englewood, New Jersey) was injected, followed by the MRSA inoculum (3 106
CFU in 100 l) through the same needle. The needle was then flushed with 100
l of 0.9% NaCl to ensure all bacteria reached the tibial cavity. The skin was
subsequently closed with Vicryl 4/0.
Debridement and bone cement injection. The tibias were debrided 21 days
after the first operation. A 3-cm incision was made over the pattello-tibial
tendon, parallel to the tibial shaft. Subsequently, access to the tibal cavity was
gained through the pattello-tibial tendon with a small drill (2.0-mm diameter),
which was gradually increased to 3.5-mm diameter. The tibial canal was then
debrided by reaming with stainless steel brushes (Abrasives Center, Maastricht,
The Netherlands) increasing in size up to 4.0-mm diameter. It was attempted to
remove as much infected and necrotic tissue as possible. Tissue remnants were
whipped from the drills and brushes with conventional swabs and sent for cul-
ture. The canal was then flushed with 100 ml 0.9% saline solution to remove any
loose debris and remaining bone marrow. A suction cuvette was placed in the
tibial canal until the cement was injected.
The calcium phosphate bone cement (2.5 g) (Calcibon, Biomet Merck, Darm-
stadt, Germany) was prepared under strict sterile conditions on the surgical table
according to the manufacture’s instructions. The cement paste was injected into
the tibial cavity through a stainless steel cannula with an inside diameter of 2.4
mm while slowly retracting the syringe. The syringe was weighed before and after
injection to determine the amount of injected cement. Hereafter, the fascia and
skin were closed with Vicryl 4/0. Pre- and postoperative X-rays were also taken
to confirm the correct position of the bone cement and for the initial assessment
of radiological osteomyelitis signs (Fig. 1).
Follow-up. All animals were monitored daily and examined at preset time
points, days 1, 2, 4, and 7 and thereafter every 7 days. After the second surgical
procedure on day 21 they were again examined more frequently, days 22, 24, and
28 and subsequently every 7 days until autopsy on day 42. During the examina-
tions, the wound was inspected for signs of infection, the animals were weighed,
and blood was drawn from the auricular vein for WBC and ESR determination.
Autopsy and sample acquisition. On day 42, the animals were euthanized, first
by sedation with a subcutaneous injection of 2.5 mg/kg xylazine and 62.5 mg/kg
ketamine, and then sacrificed by an intravenous injection of 75 mg/kg pentobar-
bital (Nembutal, Ceva Sante Animale BV, Naaldwijk, The Netherlands). The
right tibias were excised under strict aseptic conditions. After excision, radio-
graphs were taken to assess radiological disease severity.
A high-speed dental drill was used to saw a standardized square bone sample
(1 g) from the proximal medial tibia for quantitative microbiological analyses.
The saw was cooled with physiological saline, and care was also taken not to
damage the bone cement. Subsequently, the saw-cut surfaces and interior of the
bone sample were cultured with conventional swabs. A transverse section adja-
cent to the removed bone sample was processed for histological analyses. A
strictly standardized protocol was enforced to insure that comparable samples
FIG. 1. Preoperative lateral radiograph (A) of the right tibia from
a sham-treated rabbit. Periosteal reaction is present (arrowheads), and
the drill hole can still be seen as a slight shadow (arrow). The postop-
erative lateral radiograph (B) of the same rabbit shows the cement in
situ (arrows).
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were acquired. The samples for quantitative microbiological analysis were then
further processed by a technician blinded to the assigned groups.
Radiology. The radiographs obtained at the second procedure and at autopsy
were randomized, scored by an independent orthopedic surgeon. The standard
osteomyelitis disease severity score of Norden et al. was used; this score is based
on the presence of sequestra, periosteal new bone formation, and destruction of
bone (18). Involvement of the proximal, mid-, and distal tibia was also scored,
resulting in a maximum score of seven points. Animals were considered to have
radiological osteomyelitis when the severity score was 3 or more.
Microbiology. The conventional swabs were plated on horse blood agar and
incubated for at least 48 h at 37°C. To further increase the sensitivity of this
method, the tips were also incubated in 10 ml brain heart infusion (BHI) broth
on a shaker for 7 days at 37°C.
The quantitative assay consisted of weighing the standardized bone sample
and then homogenizing it in 50 ml PBS at high speed (15,000 rpm) for 2 min
(Sorval Omnimix, Dupont Instruments, Newton, Connecticut). Bacterial load
was determined by serially diluting the homogenate and plating a standard
volume (10 l in triplicate) on blood agar, followed by incubation for 48 h at
37°C. The colonies were counted and bacterial load was calculated as the number
of CFU per gram of bone tissue. After each run, the Omnimixer was thoroughly
cleaned and subsequently sterilized to prevent any possible cross contamination
between samples. The detection limit of this method was approximately 2.5 103
CFU/g bone depending on the mass of the specific homogenized bone section.
For statistical analysis, the negative samples (without growth of microorganisms)
of the quantitative assay were considered to have the detection limit value
(2.5  103 CFU/g bone) of the bacterial load. Additionally, a 1-ml sample of
FIG. 2. Changes in body weight and white blood cell (WBC) count are plotted over time in A and B, respectively. The first and second surgical
procedure are indicated as OP1 and OP2, respectively. There were no significant differences between groups. Values are the means standard deviation.
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bone homogenate was cultured in 10 ml BHI broth for 7 days at 37°C in a shaker
to detect bacteria below the detection limit of the quantitative method.
Identification of S. aureus was based on the coagulase test (Staphytect, Oxoid
Ltd., Basingstoke, Hamshire, United Kingdom). To genotype the strains, SmaI
digests of total bacterial DNA were resolved by a pulsed-field gel electrophoresis
performed as previously described by Ichiyama et al. (6). Strains were considered
clonal if less than two bands varied on a gel.
Histology. Bone slices were fixed in buffered formalin for two days, decalcified
in EDTA, embedded in paraffin, mounted on slides, and stained with hematox-
ylin and eosin. The disease severity score described by Smeltzer and coworkers
was used to rate signs of infection (20). This score is divided into four categories
that are scored with zero to four points: intra-osseous acute inflammation,
intra-osseous chronic inflammation, periosteal inflammation, and bone necrosis.
The diagnosis of osteomyelitis was considered positive when the Smeltzer score
was at least 4. The maximum score of 16 signifies severe osteomyelitis with
intramedullar abscesses, fibrosis, and multiple foci of sequestra. Slides were
randomized and subsequently scored by an independent pathologist.
Statistical analysis. The results were analyzed using the Statistical Package for
the Social Sciences (SPSS) version 10.1 for Windows. The Mann-Whitney tests
for independent samples were performed for comparison of the CFU count
between groups, as these data were not normally distributed. This test was also
used to test the ordinal radiological and histological score between different groups.
The Wilcoxon signed rank test was performed for comparison of radiological scores
within groups. Furthermore, analysis of variance tests using Bonferroni’s posthoc
test were performed for comparison of blood parameters between groups and
paired Student t tests were performed for comparison of different time points
within groups. Differences were considered significant at P  0.05.
RESULTS
General. All animals tolerated both operations well, display-
ing no signs of systemic infection. One rabbit in the gentami-
cin-treated group had wound dehiscence after the second pro-
cedure. This wound was debrided, flushed with physiological
saline, and subsequently closed subcutaneously, after which the
rabbit recovered well. None of the rabbits developed soft tissue
swelling or fistulae, and clinically the infection was maintained
in the tibia.
The rabbits did display a tendency to slight weight loss after
each procedure, recovering to normal after 7 to 14 days (Fig.
2A). The initial weights were not significantly different from
the weight at day 21 or day 42 except for the gentamicin group,
which showed an increase at day 21. Furthermore, there were
no significant differences in weight between the different treat-
ment regimens.
The pattern of changes in weight after each procedure are
also reflected in the WBC (Fig. 2B), which increased after each
procedure and then returned to normal at day 21 and at day 42.
The ESR showed a similar pattern, although none of the
changes were significant (data not shown). Both the WBC and
the ESR patterns were seen in all treatment regimens.
The sham-treated group had a mean of 1.8  1.1 g of wet
bone cement injected. The hLF1-11 had 2.2  0.2 g of wet
bone cement injected, representing a mean total dose of 19.0
1.8 mg hLF1-11/kg body weight. The gentamicin-treated ani-
mals had a similar amount of wet cement injected, 2.4  0.3 g,
with a mean of 21.9  2.3 mg gentamicin sulfate/kg body
weight.
Microbiology. The bacterial load per gram of bone is plotted
in Fig. 3. The median bacterial load of both the 3-week control
and the sham group was 1.3  105 and 2.4  106 CFU/g bone,
respectively. The hLF1-11 group had a significantly lower bac-
terial load (median of 3.0  103 CFU/g bone) compared to
both the control and sham groups (P  0.01). Seven out of
eight animals did not have quantifiable bacteria using this
method. Furthermore, the gentamicin-treated animals also had
a significantly lower bacterial load (median of 2.7 103 CFU/g
bone) compared to both the control and sham-treated groups
(P  0.004). Two animals out of the eight gentamicin-treated
animals still had quantifiable bacteria in their tibia. There was
FIG. 3. Quantitative microbiological analyses of the cultured bone homogenate. The individual data points (circles) and the medians (black
bars) are indicated. The dotted line represents the approximate detection limit (2.5  103 CFU/g bone) of the assay; animals with values below this
limit had negative cultures with the quantitative method (no growth). Both the 3-week control and the sham-treated animals had a significantly higher
bacterial load than the hLF1-11- (P 0.01) or gentamicin-treated animals (P 0.004). There was no significant difference in bacterial load between the
3-week controls and the sham-treated animals (P  0.6), nor was there a difference between the gentamicin- and hLF1-11-treated animals (P  0.6).
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no significant difference in bacterial load between gentamicin-
and hLF1-11-treated animals (P  0.6).
At autopsy, two out of eight gentamicin-treated animals still
yielded MRSA at autopsy. Similarly, MRSA was cultured in
three out of eight animals in the hLF1-11 group. On the other
hand, MRSA was cultured from all five control animals. More-
over, all six sham-treated animals yielded MRSA after 6 weeks.
All bacteria isolated at autopsy were found to be coagulase
positive. These S. aureus strains were subsequently also shown
to be clonal (and identical to the strain which was used to
induce the osteomyelitis) by pulsed-field gel electrophoresis,
indicating that there was no contamination with other bacterial
strains during the operative procedures.
Radiology. The radiographs obtained at autopsy shown in
Fig. 4 illustrate the variety of disease severity found in this
study. The average radiographical scores are plotted in Fig. 5.
The severity score for both the sham- and gentamicin-treated
animals increased significantly from days 21 to 42 (P  0.039
and P  0.011, respectively). In contrast, the score for the
hLF1-11-treated animals did not increase (P  0.29). Further-
more, at autopsy the score of the hLF1-11 group was also
significantly lower than that of both the sham- and gentamicin-
treated groups, P  0.043 and P  0.035, respectively. In the
control group four out of five and the sham-treated group five
out of six animals had a score higher than 3, indicating appar-
ent osteomyelitis. In the gentamicin group, five out of eight
animals still had a score higher than 3 points, whereas in the
hLF1-11-treated animals only three out of eight animals still
had radiological signs of osteomyelitis.
Histology. Examples of the histological sections are dis-
played in Fig. 6, illustrating that disease severity varied con-
siderably between animals. Some specimens displayed all signs
of osteomyelitis; periosteal reaction, intramedullary or subpe-
riosteal abscesses, sequestra, and fibrosis, as opposed to others
that only had minor signs of osteomyelitis in the same group.
This variation is reflected in the disease severity scores,
which are plotted in Fig. 7. However, both gentamicin and
hLF1-11 significantly reduced the disease severity score com-
pared to the sham and the control groups (P  0.04 and P 
0.01, respectively). There was no significant difference in dis-
ease severity score between hLF1-11- and gentamicin-treated
animals or between control and sham-treated animals.
A histological score of 4 or more points was indicative of
osteomyelitis (20); this was seen in four out of five control
animals and in five out of six sham-treated animals. In the
gentamicin-treated animals three out of eight animals and in
the hLF1-11 group only 2 out of eight still had osteomyelitis
based on the histological score alone.
DISCUSSION
In this study, we induced chronic osteomyelitis in the tibia as
described by Norden et al. (18). This model has been used
extensively for evaluating experimental treatment protocols for
osteomyelitis (17). We modified the treatment protocol by
local debridement and subsequent injection of calcium phos-
phate cement containing the antimicrobial agent. The patho-
gen used in this study is an MRSA strain isolated from a
FIG. 4. Representative radiographs of excised tibias. In the 3-week
control animal (A), periosteal reaction is visible (white arrowheads).
More severe signs of chronic osteomyelitis are seen in the 6-week
sham-treated animal (B). The periosteal reaction (arrowheads) is ex-
acerbated and a sequestrum is present (arrows). Also, there is a moth-
eaten appearance with bony destruction (stars). More proximal, there
is evidence of bone cement resorption (block arrows). Slight periosteal
elevation (arrowheads) was seen in the gentamicin-treated tibia (C)
distal to the bone cement, whereas this hLF1-11-treated animal (D)
did not show signs of osteomyelitis.
FIG. 5. Radiographic osteomyelitis scoring per Norden et al. was
used to analyze disease severity at day 21 (white bars) and day 42
(black bars). The maximum score of 7 reflects severe chronic osteo-
myelitis in the entire tibia with periosteal new bone, sequestra, and foci
of necrosis. The disease severity score increased from day 21 to day 42
in both the sham-treated group (P  0.04) and the gentamicin group
(P  0.011). Furthermore, at day 42, the hLF1-11-treated animals had
a significantly better score than both the sham-treated (P  0.043) and
the gentamicin-treated animals (P 0.035). Given are the mean values
and standard deviation.
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patient with osteomyelitis that had been used in a previous
osteomyelitis study and shown to be sufficiently virulent (U.
Joosten, personal communication).
MRSA was recovered from all control and sham-treated
animals. However, in both groups, one animal each had a low
bacterial load, which was also reflected in their radiological
and histological scores. Since the gold standard for osteomy-
elitis was a positive culture for MRSA, we concluded that our
model was valid, with a 100% infection rate in both the control
and the sham-treated groups (no antibiotic).
The data presented in this study clearly demonstrate the
ability of hLF1-11 to treat MRSA osteomyelitis in this model.
The hLF1-11 treatment not only significantly reduced bacterial
load compared to controls, but also significantly reduced the
radiological and histopathological score. In this study, the per-
formance of hLF1-11 was comparable to that of gentamicin,
even though the MRSA strain was gentamicin susceptible.
Regarding the hLF1-11 group, in five out of eight animals no
growth was detectable. And, of the three MRSA-positive rab-
bits, only one rabbit was found to have a high bacterial load.
This rabbit also had an initial high radiological score of 5.5 at
the onset of treatment. The other two rabbits did not have
quantifiable bacteria but showed growth of MRSA in the broth
culture and also had radiological and histological signs of os-
teomyelitis.
In the gentamicin group, five out of eight animals were still
found to have radiological osteomyelitis and three out of eight
animals had histological signs of infection. Only two of these
animals had positive cultures for MRSA. Since radiological
signs were seen distal of the bone cement, it is suggested that
the infection survived in the distal diaphysis, a location at
which gentamicin levels could be substantially lower (26).
Some osteomyelitis signs may have been missed on histology,
as only sections at one level next to the bone cement were
examined, whereas radiology picked up osteomyelitis signs of
the entire femur. The two methods supplemented each other,
allowing reliable interpretation of the data.
Nibbering et al. found a 2.5 log reduction of bacterial load in
the mouse thigh model using very low systemic dosages of
hLF1-11 (0.1 to 1 nmol) (16). An immune-inciting effect was
presumed to be responsible for the reduction of bacterial load
in this mouse thigh model (16), whereas the direct killing effect
of higher concentrations of hLF1-11 is presumed to play a role
in the efficacy of hLF1-11 in the prophylactic osteomyelitis
rabbit model (21). In this study both mechanisms may have
acted simultaneously, rapid bacterial killing occurring at the
level of the tibia and due to the bone-serum gradient, low
systemic concentrations of hLF1-11 could then incite an im-
mune response (26). However, more pharmacokinetic studies
are required to elucidate the mechanism of action in this
model.
A disadvantage of local delivery of conventional antibiotics
is the low-level subinhibitory release after the burst release has
subsided. This phenomena is well-known to occur in the case
of gentamicin release from PMMA, and release can even con-
tinue for years, thereby also inducing and selecting antimicro-
bial resistance of bacteria (14, 15, 23, 25). However, the ad-
vantage of antimicrobial peptides is their intrinsic low tendency
to induce resistance, despite prolonged passages of bacteria
through subinhibitory concentrations (3, 4, 31). Furthermore,
we used a resorbable cement, which ensures that the antibiotic
cannot be released indefinitely (19).
Over the past decade, numerous naturally occurring antimi-
crobial peptides have been identified, emphasizing their piv-
FIG. 6. Representative photomicrographs (hematoxylin and eosin
stained) of transverse sections of the tibial cortex. Panel A depicts a
3-week control animal; note the marked periosteal reaction (stars)
surrounding the largely necrotic cortex. Also, abscesses (white arrows)
are present both intramedullarly and subperiosteally. The intramedul-
lary canal is filled with fibrotic tissue (arrowheads) and some new bone
formation also can be seen (black arrow). Panel B depicts a sham-
treated specimen. Note the bone marrow versus bone cement interface
(white block arrows). Similar pathology can be seen with periosteal
bone formation (stars), abscesses (white arrows), intramedullary fibro-
sis (arrowheads), and intramedullary new bone formation (black ar-
rows). Panel C shows an hLF1-11-treated specimen. Note the absence
of periosteal inflammation (white arrows); no other pathology can be
seen. A gentamicin-treated specimen without periosteal inflammation
(white arrows) is depicted in panel D. Magnification: A and B, 25; C
and D, 50.
FIG. 7. Histopathological data as scored using the score of Smelt-
zer et al. (mean  standard deviation). The maximum score is 16,
indicating severe osteomyelitis with intramedullary abscess and fibro-
sis, severe periosteal reaction with subperiosteal abscess, and multiple
foci of necrotic bone. Both the hLF1-11- and gentamicin-treated ani-
mals have a significantly lower score than the 3-week control and the
sham groups, P  0.04 and P  0.01, respectively.
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otal role as part of the first line of defense in our innate
immune system (4, 31). Several research groups have specifi-
cally described options for the development of antimicrobial
peptides as new antimicrobial agents and investigated their
efficacy in vivo. Van’t Hof et al. have reviewed a large number
of antimicrobial peptides currently under investigation (24).
The rBPI21 antimicrobial peptide has reached phase III clinical
trials and has shown promising clinical results, improving the
outcome of meningococcal sepsis in children (10). The rise of
antimicrobial resistance has further emphasized the need for
new antimicrobial agents. MRSA has already emerged in large
areas of the world, and with the additional increase of infec-
tions due to S. aureus with reduced susceptibility or resistance
to glycopeptides, concern about the development of strains
resistant to all available antibiotics has arisen (29).
This study demonstrates the ability of hLF1-11 incorporated
into calcium phosphate cement to treat MRSA osteomyelitis in
rabbits. hLF1-11 improved the clinical outcome radiologically,
microbiologically, and histologically compared to control ani-
mals. Furthermore, the efficacy of hLF1-11 was comparable
to that of gentamicin in this model. The results of this study
thus warrant further preclinical investigations into the use of
hLF1-11 for the treatment of osteomyelitis.
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